Toxoplasmosis an overlooked disease: Seroprevalence in cancer patients

Bibliographic Information
Authors: Malek R.A.; Wassef R.; Rizk E.; Sabry H.; Tadros N.; Boghdady A.
Journal: Asian Pacific Journal of Cancer Prevention
Publisher: Asian Pacific Organization for Cancer Prevention
Publication Date: 2018
Volume / Issue: Volume 19 / Issue 7
Pages: 1987–1991
ISSN: 15137368
DOI: 10.22034/APJCP.2018.19.7.1987
Scopus: View on Scopus
PubMed: 30051689
Document Type: Article
Authors and Affiliations
Malek R.A., Department of Clinical Oncology, Kasr Al-Ainy Faculty of Medicine, Cairo University, Egypt; Wassef R., Department of Medical Parasitology, Faculty of Medicine, Helwan University, Egypt; Rizk E., Department of Medical Parasitology, Kasr Al-Ainy Faculty of Medicine, Cairo University, Egypt; Sabry H., Department of Medical Parasitology, Theodor Bilharz Research Institute, Egypt; Tadros N., Department of Medical Parasitology, Theodor Bilharz Research Institute, Egypt; Boghdady A., Department of Medical Parasitology, Kasr Al-Ainy Faculty of Medicine, Cairo University, Egypt
Abstract
Background: Toxoplasmosis is one of the most important cosmopolitan life-threatening diseases in immune-compromised patients. It is caused by an intracellular protozoon: Toxoplasma gondii (T. gondii). The parasite can cause pneumonia, encephalitis or disseminated disease in immune-deficient patients and dangerous congenital anomalies in infants born to mothers infected during early pregnancies. The present study aims to evaluate the prevalence of toxoplasmosis in Egyptian cancer patients and to correlate the prevalence with type of malignancy and the different cancer treatment modalities. Materials and Methods: Blood samples from 150 cancer patients and 50 control subjects have been examined for presence of anti-toxoplasma antibodies using a lateral flow chromatographic immunoassay. Results: Among cancer patients included in this study, the prevalence of anti- T.gondii antibodies was 20% for IgG and 4% for IgM, while in the control group it was 8% and 2% in the same order. This difference was statistically significant for IgG (P =0.003) but not for IgM (P = 0.44). Patients with solid organ tumors treated with chemotherapy had the highest prevalence rate of toxoplasmosis (28%). It was also found higher in males (26%) than females (10%) and higher among urban (18%) than rural dwellers (16%). Conclusion: Cancer patients showed a significantly higher rate of infection with T. gondii than their cross-matched control. For that reason, we recommend the inclusion of a screening test for toxoplasmosis in their routine workup. © 2018 Asian Pacific Organization for Cancer Prevention.
Keywords
Cancer; Chemotherapy; Prevalence; Radiation; Toxoplasma gondii; Biomarkers, Tumor; Case-Control Studies; Cross-Sectional Studies; Egypt; Female; Follow-Up Studies; Humans; Immunoglobulin G; Immunoglobulin M; Male; Neoplasms; Prognosis; Risk Factors; Seroepidemiologic Studies; Toxoplasmosis; tumor marker; blood; case control study; cross-sectional study; follow up; human; neoplasm; pathophysiology; risk factor; seroepidemiology
Citation Information
Scopus Citations: 29
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
